Want to see FR:DIM full AI Analyst Report?
Top Page
Sartorius Stedim Biotech
(DIM)
Select Model
Select Model
Rating:56Neutral
Price Target:
€195.00
▲(3.34% Upside)
Action:Reiterated
Date:04/25/26
The score is primarily supported by improving fundamentals (sharp TTM revenue rebound and still solid operating margins, with leverage improving), but is held back by ongoing post-peak margin/ROE compression and weak free-cash-flow conversion. Technicals are also a meaningful drag given the price sitting below major moving averages with subdued momentum, and valuation remains expensive with a high P/E and minimal dividend yield.
Positive Factors
Recurring Consumables Revenue
A high-share recurring consumables model creates predictable, repeat revenue tied to customers' production runs. Installed capital placements drive long-term pull-through for disposables, smoothing demand cycles and supporting durable revenue and margin visibility over multiple quarters.
Negative Factors
Margin Compression vs Peak
Meaningful, multi-year margin erosion versus 2021–2022 peaks reduces the company's earnings power per euro of revenue. If structural (pricing, mix, or cost base shifts), this compresses long-term profitability, ROE, and available cash for reinvestment or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables Revenue
A high-share recurring consumables model creates predictable, repeat revenue tied to customers' production runs. Installed capital placements drive long-term pull-through for disposables, smoothing demand cycles and supporting durable revenue and margin visibility over multiple quarters.
Read all positive factors
Sartorius Stedim Biotech (DIM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€17.84B
Dividend Yield0.31%
Average Volume (3M)78.09K
Price to Earnings (P/E)68.8
Beta (1Y)1.49
Revenue Growth4.43%
EPS Growth31.23%
CountryFR
Employees9,961
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.75
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€225.67Price Target Upside19.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.08
Revenue Forecast (FY)€3.17B
Sartorius Stedim Biotech Business Overview & Revenue Model
Company Description
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental component...
How the Company Makes Money
Sartorius Stedim Biotech primarily generates revenue by selling bioprocessing products and related services to biopharmaceutical and biotechnology customers. A major component of its model is a recurring consumables stream: single-use assemblies (...
Sartorius Stedim Biotech Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
66
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.98B | 2.97B | 2.78B | 2.78B | 3.49B | 2.89B |
| Gross Profit | 1.33B | 1.35B | 1.21B | 1.23B | 1.82B | 1.55B |
| EBITDA | 848.40M | 867.10M | 670.50M | 755.70M | 1.33B | 811.96M |
| Net Income | 268.10M | 265.60M | 175.10M | 309.70M | 876.10M | 414.40M |
Balance Sheet | ||||||
| Total Assets | 8.19B | 8.02B | 8.26B | 7.74B | 5.07B | 3.95B |
| Cash, Cash Equivalents and Short-Term Investments | 521.20M | 434.20M | 688.80M | 126.10M | 133.00M | 237.35M |
| Total Debt | 2.61B | 2.60B | 2.87B | 3.68B | 1.14B | 625.52M |
| Total Liabilities | 4.05B | 3.89B | 4.23B | 5.07B | 2.55B | 2.22B |
| Stockholders Equity | 4.11B | 4.09B | 3.99B | 2.64B | 2.45B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | 213.00M | 145.40M | 475.30M | 156.10M | 181.70M | 371.98M |
| Operating Cash Flow | 610.50M | 538.60M | 815.10M | 629.70M | 612.30M | 695.97M |
| Investing Cash Flow | -402.00M | -397.70M | -340.00M | -2.72B | -957.50M | -465.23M |
| Financing Cash Flow | -391.20M | -389.20M | 84.90M | 1.99B | 220.70M | -69.27M |
Sartorius Stedim Biotech Technical Analysis
Positive
188.70
Price Trends
171.84
Positive
171.18
Positive
184.64
Negative
Market Momentum
2.16
Negative
58.97
Neutral
47.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Positive. The current price of 188.7 is above the 20-day moving average (MA) of 174.95, above the 50-day MA of 171.84, and above the 200-day MA of 184.64, indicating a neutral trend. The MACD of 2.16 indicates Negative momentum. The RSI at 58.97 is Neutral, neither overbought nor oversold. The STOCH value of 47.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:DIM.
Sartorius Stedim Biotech Peers Comparison
UnderperformOutperform
Sector (55)
FR:DIM
Sartorius Stedim Biotech
189.30
-6.05
-3.10%
FR:BIM
bioMerieux
70.85
-47.13
-39.95%
FR:ERF
Eurofins Scientific
69.50
10.04
16.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.